Dopamine-receptor stimulation: biobehavioral and biochemical consequences
Identifieur interne : 002681 ( Istex/Corpus ); précédent : 002680; suivant : 002682Dopamine-receptor stimulation: biobehavioral and biochemical consequences
Auteurs : Frédéric Calon ; Abdallah Hadj Tahar ; Pierre J. Blanchet ; Marc Morissette ; Richard Grondin ; Martin Goulet ; Jean-Pierre Doucet ; George S. Robertson ; Eric Nestler ; Thérèse Di Paolo ; Paul J. BédardSource :
- Trends in Neurosciences [ 0166-2236 ] ; 2000.
Abstract
The MPTP monkey is a well-characterized animal model of parkinsonism and provides an exceptional tool for the study of dyskinesias induced by dopamine-like agents. Several such agents have been tested during the past 15 years, and it has been found that the duration of action of these compounds is the most reliable variable with which to predict their dyskinesiogenic profile. It is proposed that l-dopa-induced dyskinesias represent a form of pathological learning caused by chronic pulsatile (non physiological) stimulation of dopamine receptors, which activates a cascade of molecular and biochemical events. These events include defective regulation of Fos proteins that belong to the ΔFosB family, increased expression of neuropeptides, and defective GABA- and glutamate-mediated neurotransmission in the output structures of the basal ganglia.
Url:
DOI: 10.1016/S1471-1931(00)00026-4
Links to Exploration step
ISTEX:F5021E916FA1644FC98FFA3C109970BDE219090ALe document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dopamine-receptor stimulation: biobehavioral and biochemical consequences</title><author><name sortKey="Calon, Frederic" sort="Calon, Frederic" uniqKey="Calon F" first="Frédéric" last="Calon">Frédéric Calon</name><affiliation><mods:affiliation>Oncology and Molecular Endocrinology Research Unit, Laval University Medical Center (CHUL), Québec, Canada GIV 4G2</mods:affiliation></affiliation><affiliation><mods:affiliation>Faculty of Pharmacy, Laval University, Québec, Canada GIK 7P4</mods:affiliation></affiliation></author><author><name sortKey="Tahar, Abdallah Hadj" sort="Tahar, Abdallah Hadj" uniqKey="Tahar A" first="Abdallah Hadj" last="Tahar">Abdallah Hadj Tahar</name><affiliation><mods:affiliation>Neuroscience Research Unit, Laval University Medical Center (CHUL), Québec, Canada G1V 4G2</mods:affiliation></affiliation><affiliation><mods:affiliation>Dept of Medicine, Faculty of Medicine, Laval University, Québec, Canada GIK 7P4</mods:affiliation></affiliation></author><author><name sortKey="Blanchet, Pierre J" sort="Blanchet, Pierre J" uniqKey="Blanchet P" first="Pierre J." last="Blanchet">Pierre J. Blanchet</name><affiliation><mods:affiliation>Neuroscience Research Unit, Laval University Medical Center (CHUL), Québec, Canada G1V 4G2</mods:affiliation></affiliation><affiliation><mods:affiliation>Dept of Medicine, Faculty of Medicine, Laval University, Québec, Canada GIK 7P4</mods:affiliation></affiliation></author><author><name sortKey="Morissette, Marc" sort="Morissette, Marc" uniqKey="Morissette M" first="Marc" last="Morissette">Marc Morissette</name><affiliation><mods:affiliation>Oncology and Molecular Endocrinology Research Unit, Laval University Medical Center (CHUL), Québec, Canada GIV 4G2</mods:affiliation></affiliation><affiliation><mods:affiliation>Faculty of Pharmacy, Laval University, Québec, Canada GIK 7P4</mods:affiliation></affiliation></author><author><name sortKey="Grondin, Richard" sort="Grondin, Richard" uniqKey="Grondin R" first="Richard" last="Grondin">Richard Grondin</name><affiliation><mods:affiliation>Oncology and Molecular Endocrinology Research Unit, Laval University Medical Center (CHUL), Québec, Canada GIV 4G2</mods:affiliation></affiliation><affiliation><mods:affiliation>Faculty of Pharmacy, Laval University, Québec, Canada GIK 7P4</mods:affiliation></affiliation><affiliation><mods:affiliation>Neuroscience Research Unit, Laval University Medical Center (CHUL), Québec, Canada G1V 4G2</mods:affiliation></affiliation><affiliation><mods:affiliation>Dept of Medicine, Faculty of Medicine, Laval University, Québec, Canada GIK 7P4</mods:affiliation></affiliation></author><author><name sortKey="Goulet, Martin" sort="Goulet, Martin" uniqKey="Goulet M" first="Martin" last="Goulet">Martin Goulet</name><affiliation><mods:affiliation>Oncology and Molecular Endocrinology Research Unit, Laval University Medical Center (CHUL), Québec, Canada GIV 4G2</mods:affiliation></affiliation><affiliation><mods:affiliation>Faculty of Pharmacy, Laval University, Québec, Canada GIK 7P4</mods:affiliation></affiliation></author><author><name sortKey="Doucet, Jean Pierre" sort="Doucet, Jean Pierre" uniqKey="Doucet J" first="Jean-Pierre" last="Doucet">Jean-Pierre Doucet</name><affiliation><mods:affiliation>Dept of Pharmacology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada</mods:affiliation></affiliation></author><author><name sortKey="Robertson, George S" sort="Robertson, George S" uniqKey="Robertson G" first="George S." last="Robertson">George S. Robertson</name><affiliation><mods:affiliation>Dept of Pharmacology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada</mods:affiliation></affiliation></author><author><name sortKey="Nestler, Eric" sort="Nestler, Eric" uniqKey="Nestler E" first="Eric" last="Nestler">Eric Nestler</name><affiliation><mods:affiliation>Laboratory of Molecular Psychiatry and Yale Center for Genes and Behavior, Yale University School of Medicine and Connecticut Mental Health Center, New Haven, CT 06508, USA</mods:affiliation></affiliation></author><author><name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name><affiliation><mods:affiliation>Oncology and Molecular Endocrinology Research Unit, Laval University Medical Center (CHUL), Québec, Canada GIV 4G2</mods:affiliation></affiliation><affiliation><mods:affiliation>Faculty of Pharmacy, Laval University, Québec, Canada GIK 7P4</mods:affiliation></affiliation></author><author><name sortKey="Bedard, Paul J" sort="Bedard, Paul J" uniqKey="Bedard P" first="Paul J." last="Bédard">Paul J. Bédard</name><affiliation><mods:affiliation>Neuroscience Research Unit, Laval University Medical Center (CHUL), Québec, Canada G1V 4G2</mods:affiliation></affiliation><affiliation><mods:affiliation>Dept of Medicine, Faculty of Medicine, Laval University, Québec, Canada GIK 7P4</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:F5021E916FA1644FC98FFA3C109970BDE219090A</idno><date when="2000" year="2000">2000</date><idno type="doi">10.1016/S1471-1931(00)00026-4</idno><idno type="url">https://api-v5.istex.fr/document/F5021E916FA1644FC98FFA3C109970BDE219090A/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">002681</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002681</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Dopamine-receptor stimulation: biobehavioral and biochemical consequences</title><author><name sortKey="Calon, Frederic" sort="Calon, Frederic" uniqKey="Calon F" first="Frédéric" last="Calon">Frédéric Calon</name><affiliation><mods:affiliation>Oncology and Molecular Endocrinology Research Unit, Laval University Medical Center (CHUL), Québec, Canada GIV 4G2</mods:affiliation></affiliation><affiliation><mods:affiliation>Faculty of Pharmacy, Laval University, Québec, Canada GIK 7P4</mods:affiliation></affiliation></author><author><name sortKey="Tahar, Abdallah Hadj" sort="Tahar, Abdallah Hadj" uniqKey="Tahar A" first="Abdallah Hadj" last="Tahar">Abdallah Hadj Tahar</name><affiliation><mods:affiliation>Neuroscience Research Unit, Laval University Medical Center (CHUL), Québec, Canada G1V 4G2</mods:affiliation></affiliation><affiliation><mods:affiliation>Dept of Medicine, Faculty of Medicine, Laval University, Québec, Canada GIK 7P4</mods:affiliation></affiliation></author><author><name sortKey="Blanchet, Pierre J" sort="Blanchet, Pierre J" uniqKey="Blanchet P" first="Pierre J." last="Blanchet">Pierre J. Blanchet</name><affiliation><mods:affiliation>Neuroscience Research Unit, Laval University Medical Center (CHUL), Québec, Canada G1V 4G2</mods:affiliation></affiliation><affiliation><mods:affiliation>Dept of Medicine, Faculty of Medicine, Laval University, Québec, Canada GIK 7P4</mods:affiliation></affiliation></author><author><name sortKey="Morissette, Marc" sort="Morissette, Marc" uniqKey="Morissette M" first="Marc" last="Morissette">Marc Morissette</name><affiliation><mods:affiliation>Oncology and Molecular Endocrinology Research Unit, Laval University Medical Center (CHUL), Québec, Canada GIV 4G2</mods:affiliation></affiliation><affiliation><mods:affiliation>Faculty of Pharmacy, Laval University, Québec, Canada GIK 7P4</mods:affiliation></affiliation></author><author><name sortKey="Grondin, Richard" sort="Grondin, Richard" uniqKey="Grondin R" first="Richard" last="Grondin">Richard Grondin</name><affiliation><mods:affiliation>Oncology and Molecular Endocrinology Research Unit, Laval University Medical Center (CHUL), Québec, Canada GIV 4G2</mods:affiliation></affiliation><affiliation><mods:affiliation>Faculty of Pharmacy, Laval University, Québec, Canada GIK 7P4</mods:affiliation></affiliation><affiliation><mods:affiliation>Neuroscience Research Unit, Laval University Medical Center (CHUL), Québec, Canada G1V 4G2</mods:affiliation></affiliation><affiliation><mods:affiliation>Dept of Medicine, Faculty of Medicine, Laval University, Québec, Canada GIK 7P4</mods:affiliation></affiliation></author><author><name sortKey="Goulet, Martin" sort="Goulet, Martin" uniqKey="Goulet M" first="Martin" last="Goulet">Martin Goulet</name><affiliation><mods:affiliation>Oncology and Molecular Endocrinology Research Unit, Laval University Medical Center (CHUL), Québec, Canada GIV 4G2</mods:affiliation></affiliation><affiliation><mods:affiliation>Faculty of Pharmacy, Laval University, Québec, Canada GIK 7P4</mods:affiliation></affiliation></author><author><name sortKey="Doucet, Jean Pierre" sort="Doucet, Jean Pierre" uniqKey="Doucet J" first="Jean-Pierre" last="Doucet">Jean-Pierre Doucet</name><affiliation><mods:affiliation>Dept of Pharmacology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada</mods:affiliation></affiliation></author><author><name sortKey="Robertson, George S" sort="Robertson, George S" uniqKey="Robertson G" first="George S." last="Robertson">George S. Robertson</name><affiliation><mods:affiliation>Dept of Pharmacology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada</mods:affiliation></affiliation></author><author><name sortKey="Nestler, Eric" sort="Nestler, Eric" uniqKey="Nestler E" first="Eric" last="Nestler">Eric Nestler</name><affiliation><mods:affiliation>Laboratory of Molecular Psychiatry and Yale Center for Genes and Behavior, Yale University School of Medicine and Connecticut Mental Health Center, New Haven, CT 06508, USA</mods:affiliation></affiliation></author><author><name sortKey="Di Paolo, Therese" sort="Di Paolo, Therese" uniqKey="Di Paolo T" first="Thérèse" last="Di Paolo">Thérèse Di Paolo</name><affiliation><mods:affiliation>Oncology and Molecular Endocrinology Research Unit, Laval University Medical Center (CHUL), Québec, Canada GIV 4G2</mods:affiliation></affiliation><affiliation><mods:affiliation>Faculty of Pharmacy, Laval University, Québec, Canada GIK 7P4</mods:affiliation></affiliation></author><author><name sortKey="Bedard, Paul J" sort="Bedard, Paul J" uniqKey="Bedard P" first="Paul J." last="Bédard">Paul J. Bédard</name><affiliation><mods:affiliation>Neuroscience Research Unit, Laval University Medical Center (CHUL), Québec, Canada G1V 4G2</mods:affiliation></affiliation><affiliation><mods:affiliation>Dept of Medicine, Faculty of Medicine, Laval University, Québec, Canada GIK 7P4</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Trends in Neurosciences</title><title level="j" type="abbrev">TINS</title><idno type="ISSN">0166-2236</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="2000">2000</date><biblScope unit="volume">23</biblScope><biblScope unit="supplement">S1</biblScope><biblScope unit="page" from="S92">S92</biblScope><biblScope unit="page" to="S100">S100</biblScope></imprint><idno type="ISSN">0166-2236</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0166-2236</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The MPTP monkey is a well-characterized animal model of parkinsonism and provides an exceptional tool for the study of dyskinesias induced by dopamine-like agents. Several such agents have been tested during the past 15 years, and it has been found that the duration of action of these compounds is the most reliable variable with which to predict their dyskinesiogenic profile. It is proposed that l-dopa-induced dyskinesias represent a form of pathological learning caused by chronic pulsatile (non physiological) stimulation of dopamine receptors, which activates a cascade of molecular and biochemical events. These events include defective regulation of Fos proteins that belong to the ΔFosB family, increased expression of neuropeptides, and defective GABA- and glutamate-mediated neurotransmission in the output structures of the basal ganglia.</div></front></TEI><istex><corpusName>elsevier</corpusName><author><json:item><name>Frédéric Calon</name><affiliations><json:string>Oncology and Molecular Endocrinology Research Unit, Laval University Medical Center (CHUL), Québec, Canada GIV 4G2</json:string><json:string>Faculty of Pharmacy, Laval University, Québec, Canada GIK 7P4</json:string></affiliations></json:item><json:item><name>Abdallah Hadj Tahar</name><affiliations><json:string>Neuroscience Research Unit, Laval University Medical Center (CHUL), Québec, Canada G1V 4G2</json:string><json:string>Dept of Medicine, Faculty of Medicine, Laval University, Québec, Canada GIK 7P4</json:string></affiliations></json:item><json:item><name>Pierre J. Blanchet</name><affiliations><json:string>Neuroscience Research Unit, Laval University Medical Center (CHUL), Québec, Canada G1V 4G2</json:string><json:string>Dept of Medicine, Faculty of Medicine, Laval University, Québec, Canada GIK 7P4</json:string></affiliations></json:item><json:item><name>Marc Morissette</name><affiliations><json:string>Oncology and Molecular Endocrinology Research Unit, Laval University Medical Center (CHUL), Québec, Canada GIV 4G2</json:string><json:string>Faculty of Pharmacy, Laval University, Québec, Canada GIK 7P4</json:string></affiliations></json:item><json:item><name>Richard Grondin</name><affiliations><json:string>Oncology and Molecular Endocrinology Research Unit, Laval University Medical Center (CHUL), Québec, Canada GIV 4G2</json:string><json:string>Faculty of Pharmacy, Laval University, Québec, Canada GIK 7P4</json:string><json:string>Neuroscience Research Unit, Laval University Medical Center (CHUL), Québec, Canada G1V 4G2</json:string><json:string>Dept of Medicine, Faculty of Medicine, Laval University, Québec, Canada GIK 7P4</json:string></affiliations></json:item><json:item><name>Martin Goulet</name><affiliations><json:string>Oncology and Molecular Endocrinology Research Unit, Laval University Medical Center (CHUL), Québec, Canada GIV 4G2</json:string><json:string>Faculty of Pharmacy, Laval University, Québec, Canada GIK 7P4</json:string></affiliations></json:item><json:item><name>Jean-Pierre Doucet</name><affiliations><json:string>Dept of Pharmacology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada</json:string></affiliations></json:item><json:item><name>George S. Robertson</name><affiliations><json:string>Dept of Pharmacology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada</json:string></affiliations></json:item><json:item><name>Eric Nestler</name><affiliations><json:string>Laboratory of Molecular Psychiatry and Yale Center for Genes and Behavior, Yale University School of Medicine and Connecticut Mental Health Center, New Haven, CT 06508, USA</json:string></affiliations></json:item><json:item><name>Thérèse Di Paolo</name><affiliations><json:string>Oncology and Molecular Endocrinology Research Unit, Laval University Medical Center (CHUL), Québec, Canada GIV 4G2</json:string><json:string>Faculty of Pharmacy, Laval University, Québec, Canada GIK 7P4</json:string></affiliations></json:item><json:item><name>Paul J. Bédard</name><affiliations><json:string>Neuroscience Research Unit, Laval University Medical Center (CHUL), Québec, Canada G1V 4G2</json:string><json:string>Dept of Medicine, Faculty of Medicine, Laval University, Québec, Canada GIK 7P4</json:string></affiliations></json:item></author><articleId><json:string>00000264</json:string></articleId><language><json:string>eng</json:string></language><originalGenre><json:string>Review article</json:string></originalGenre><abstract>The MPTP monkey is a well-characterized animal model of parkinsonism and provides an exceptional tool for the study of dyskinesias induced by dopamine-like agents. Several such agents have been tested during the past 15 years, and it has been found that the duration of action of these compounds is the most reliable variable with which to predict their dyskinesiogenic profile. It is proposed that l-dopa-induced dyskinesias represent a form of pathological learning caused by chronic pulsatile (non physiological) stimulation of dopamine receptors, which activates a cascade of molecular and biochemical events. These events include defective regulation of Fos proteins that belong to the ΔFosB family, increased expression of neuropeptides, and defective GABA- and glutamate-mediated neurotransmission in the output structures of the basal ganglia.</abstract><qualityIndicators><score>6.476</score><pdfWordCount>11534</pdfWordCount><pdfCharCount>56157</pdfCharCount><pdfVersion>1.3</pdfVersion><pdfPageCount>9</pdfPageCount><pdfPageSize>634 x 850 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractWordCount>123</abstractWordCount><abstractCharCount>851</abstractCharCount><keywordCount>0</keywordCount></qualityIndicators><title>Dopamine-receptor stimulation: biobehavioral and biochemical consequences</title><pii><json:string>S1471-1931(00)00026-4</json:string></pii><genre><json:string>review-article</json:string></genre><serie><title>Correlation with [3H]spiperone binding</title><language><json:string>unknown</json:string></language><pages><first>294</first><last>299</last></pages></serie><host><title>Trends in Neurosciences</title><language><json:string>unknown</json:string></language><publicationDate>2000</publicationDate><issn><json:string>0166-2236</json:string></issn><pii><json:string>S0166-2236(00)X0239-1</json:string></pii><volume>23</volume><pages><first>S92</first><last>S100</last></pages><genre><json:string>journal</json:string></genre></host><categories><wos><json:string>science</json:string><json:string>neurosciences</json:string></wos><scienceMetrix><json:string>health sciences</json:string><json:string>clinical medicine</json:string><json:string>neurology & neurosurgery</json:string></scienceMetrix><inist><json:string>sciences appliquees, technologies et medecines</json:string><json:string>sciences biologiques et medicales</json:string><json:string>sciences medicales</json:string></inist></categories><publicationDate>2000</publicationDate><copyrightDate>2000</copyrightDate><doi><json:string>10.1016/S1471-1931(00)00026-4</json:string></doi><id>F5021E916FA1644FC98FFA3C109970BDE219090A</id><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api-v5.istex.fr/document/F5021E916FA1644FC98FFA3C109970BDE219090A/fulltext/pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api-v5.istex.fr/document/F5021E916FA1644FC98FFA3C109970BDE219090A/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api-v5.istex.fr/document/F5021E916FA1644FC98FFA3C109970BDE219090A/fulltext/tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Dopamine-receptor stimulation: biobehavioral and biochemical consequences</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>ELSEVIER</publisher><availability><p>©2000 Elsevier Science Ltd. All rights reserved.</p></availability><date>2000</date></publicationStmt><notesStmt><note type="content">Section title: Review</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Dopamine-receptor stimulation: biobehavioral and biochemical consequences</title><author xml:id="author-0000"><persName><forename type="first">Frédéric</forename><surname>Calon</surname></persName><affiliation>Oncology and Molecular Endocrinology Research Unit, Laval University Medical Center (CHUL), Québec, Canada GIV 4G2</affiliation><affiliation>Faculty of Pharmacy, Laval University, Québec, Canada GIK 7P4</affiliation></author><author xml:id="author-0001"><persName><forename type="first">Abdallah Hadj</forename><surname>Tahar</surname></persName><affiliation>Neuroscience Research Unit, Laval University Medical Center (CHUL), Québec, Canada G1V 4G2</affiliation><affiliation>Dept of Medicine, Faculty of Medicine, Laval University, Québec, Canada GIK 7P4</affiliation></author><author xml:id="author-0002"><persName><forename type="first">Pierre J.</forename><surname>Blanchet</surname></persName><affiliation>Neuroscience Research Unit, Laval University Medical Center (CHUL), Québec, Canada G1V 4G2</affiliation><affiliation>Dept of Medicine, Faculty of Medicine, Laval University, Québec, Canada GIK 7P4</affiliation></author><author xml:id="author-0003"><persName><forename type="first">Marc</forename><surname>Morissette</surname></persName><affiliation>Oncology and Molecular Endocrinology Research Unit, Laval University Medical Center (CHUL), Québec, Canada GIV 4G2</affiliation><affiliation>Faculty of Pharmacy, Laval University, Québec, Canada GIK 7P4</affiliation></author><author xml:id="author-0004"><persName><forename type="first">Richard</forename><surname>Grondin</surname></persName><affiliation>Oncology and Molecular Endocrinology Research Unit, Laval University Medical Center (CHUL), Québec, Canada GIV 4G2</affiliation><affiliation>Faculty of Pharmacy, Laval University, Québec, Canada GIK 7P4</affiliation><affiliation>Neuroscience Research Unit, Laval University Medical Center (CHUL), Québec, Canada G1V 4G2</affiliation><affiliation>Dept of Medicine, Faculty of Medicine, Laval University, Québec, Canada GIK 7P4</affiliation></author><author xml:id="author-0005"><persName><forename type="first">Martin</forename><surname>Goulet</surname></persName><affiliation>Oncology and Molecular Endocrinology Research Unit, Laval University Medical Center (CHUL), Québec, Canada GIV 4G2</affiliation><affiliation>Faculty of Pharmacy, Laval University, Québec, Canada GIK 7P4</affiliation></author><author xml:id="author-0006"><persName><forename type="first">Jean-Pierre</forename><surname>Doucet</surname></persName><affiliation>Dept of Pharmacology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada</affiliation></author><author xml:id="author-0007"><persName><forename type="first">George S.</forename><surname>Robertson</surname></persName><affiliation>Dept of Pharmacology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada</affiliation></author><author xml:id="author-0008"><persName><forename type="first">Eric</forename><surname>Nestler</surname></persName><affiliation>Laboratory of Molecular Psychiatry and Yale Center for Genes and Behavior, Yale University School of Medicine and Connecticut Mental Health Center, New Haven, CT 06508, USA</affiliation></author><author xml:id="author-0009"><persName><forename type="first">Thérèse</forename><surname>Di Paolo</surname></persName><affiliation>Oncology and Molecular Endocrinology Research Unit, Laval University Medical Center (CHUL), Québec, Canada GIV 4G2</affiliation><affiliation>Faculty of Pharmacy, Laval University, Québec, Canada GIK 7P4</affiliation></author><author xml:id="author-0010"><persName><forename type="first">Paul J.</forename><surname>Bédard</surname></persName><affiliation>Neuroscience Research Unit, Laval University Medical Center (CHUL), Québec, Canada G1V 4G2</affiliation><affiliation>Dept of Medicine, Faculty of Medicine, Laval University, Québec, Canada GIK 7P4</affiliation></author><idno type="istex">F5021E916FA1644FC98FFA3C109970BDE219090A</idno><idno type="DOI">10.1016/S1471-1931(00)00026-4</idno><idno type="PII">S1471-1931(00)00026-4</idno><idno type="ArticleID">00000264</idno></analytic><monogr><title level="j">Trends in Neurosciences</title><title level="j" type="abbrev">TINS</title><idno type="pISSN">0166-2236</idno><idno type="PII">S0166-2236(00)X0239-1</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="2000"></date><biblScope unit="volume">23</biblScope><biblScope unit="supplement">S1</biblScope><biblScope unit="page" from="S92">S92</biblScope><biblScope unit="page" to="S100">S100</biblScope></imprint></monogr></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2000</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>The MPTP monkey is a well-characterized animal model of parkinsonism and provides an exceptional tool for the study of dyskinesias induced by dopamine-like agents. Several such agents have been tested during the past 15 years, and it has been found that the duration of action of these compounds is the most reliable variable with which to predict their dyskinesiogenic profile. It is proposed that l-dopa-induced dyskinesias represent a form of pathological learning caused by chronic pulsatile (non physiological) stimulation of dopamine receptors, which activates a cascade of molecular and biochemical events. These events include defective regulation of Fos proteins that belong to the ΔFosB family, increased expression of neuropeptides, and defective GABA- and glutamate-mediated neurotransmission in the output structures of the basal ganglia.</p></abstract></profileDesc><revisionDesc><change when="2000">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api-v5.istex.fr/document/F5021E916FA1644FC98FFA3C109970BDE219090A/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Elsevier doc found" wicri:toSee="Elsevier, no converted or simple article"><istex:xmlDeclaration>version="1.0" encoding="utf-8"</istex:xmlDeclaration><istex:docType PUBLIC="-//ES//DTD journal article DTD version 5.0.1//EN//XML" URI="art501.dtd" name="istex:docType"></istex:docType><istex:document><article version="5.0" xml:lang="en" docsubtype="rev"><item-info><jid>TINS</jid><aid>00000264</aid><ce:pii>S1471-1931(00)00026-4</ce:pii><ce:doi>10.1016/S1471-1931(00)00026-4</ce:doi><ce:copyright type="unknown" year="2000">Elsevier Science Ltd. All rights reserved.</ce:copyright></item-info><head><ce:dochead><ce:textfn>Review</ce:textfn></ce:dochead><ce:title>Dopamine-receptor stimulation: biobehavioral and biochemical consequences</ce:title><ce:author-group><ce:author><ce:given-name>Frédéric</ce:given-name><ce:surname>Calon</ce:surname><ce:cross-ref refid="aff1"><ce:sup>a</ce:sup></ce:cross-ref><ce:cross-ref refid="aff2"><ce:sup>b</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Abdallah Hadj</ce:given-name><ce:surname>Tahar</ce:surname><ce:cross-ref refid="aff3"><ce:sup>c</ce:sup></ce:cross-ref><ce:cross-ref refid="aff4"><ce:sup>d</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Pierre J.</ce:given-name><ce:surname>Blanchet</ce:surname><ce:cross-ref refid="aff3"><ce:sup>c</ce:sup></ce:cross-ref><ce:cross-ref refid="aff4"><ce:sup>d</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Marc</ce:given-name><ce:surname>Morissette</ce:surname><ce:cross-ref refid="aff1"><ce:sup>a</ce:sup></ce:cross-ref><ce:cross-ref refid="aff2"><ce:sup>b</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Richard</ce:given-name><ce:surname>Grondin</ce:surname><ce:cross-ref refid="aff1"><ce:sup>a</ce:sup></ce:cross-ref><ce:cross-ref refid="aff2"><ce:sup>b</ce:sup></ce:cross-ref><ce:cross-ref refid="aff3"><ce:sup>c</ce:sup></ce:cross-ref><ce:cross-ref refid="aff4"><ce:sup>d</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Martin</ce:given-name><ce:surname>Goulet</ce:surname><ce:cross-ref refid="aff1"><ce:sup>a</ce:sup></ce:cross-ref><ce:cross-ref refid="aff2"><ce:sup>b</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Jean-Pierre</ce:given-name><ce:surname>Doucet</ce:surname><ce:cross-ref refid="aff5"><ce:sup>e</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>George S.</ce:given-name><ce:surname>Robertson</ce:surname><ce:cross-ref refid="aff5"><ce:sup>e</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Eric</ce:given-name><ce:surname>Nestler</ce:surname><ce:cross-ref refid="aff6"><ce:sup>f</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Thérèse</ce:given-name><ce:surname>Di Paolo</ce:surname><ce:cross-ref refid="aff1"><ce:sup>a</ce:sup></ce:cross-ref><ce:cross-ref refid="aff2"><ce:sup>b</ce:sup></ce:cross-ref></ce:author><ce:author><ce:given-name>Paul J.</ce:given-name><ce:surname>Bédard</ce:surname><ce:cross-ref refid="aff3"><ce:sup>c</ce:sup></ce:cross-ref><ce:cross-ref refid="aff4"><ce:sup>d</ce:sup></ce:cross-ref></ce:author><ce:affiliation id="aff1"><ce:label>a</ce:label><ce:textfn>Oncology and Molecular Endocrinology Research Unit, Laval University Medical Center (CHUL), Québec, Canada GIV 4G2</ce:textfn></ce:affiliation><ce:affiliation id="aff2"><ce:label>b</ce:label><ce:textfn>Faculty of Pharmacy, Laval University, Québec, Canada GIK 7P4</ce:textfn></ce:affiliation><ce:affiliation id="aff3"><ce:label>c</ce:label><ce:textfn>Neuroscience Research Unit, Laval University Medical Center (CHUL), Québec, Canada G1V 4G2</ce:textfn></ce:affiliation><ce:affiliation id="aff4"><ce:label>d</ce:label><ce:textfn>Dept of Medicine, Faculty of Medicine, Laval University, Québec, Canada GIK 7P4</ce:textfn></ce:affiliation><ce:affiliation id="aff5"><ce:label>e</ce:label><ce:textfn>Dept of Pharmacology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada</ce:textfn></ce:affiliation><ce:affiliation id="aff6"><ce:label>f</ce:label><ce:textfn>Laboratory of Molecular Psychiatry and Yale Center for Genes and Behavior, Yale University School of Medicine and Connecticut Mental Health Center, New Haven, CT 06508, USA</ce:textfn></ce:affiliation></ce:author-group><ce:abstract id="ab1" class="author" xml:lang="en"><ce:abstract-sec><ce:simple-para>The MPTP monkey is a well-characterized animal model of parkinsonism and provides an exceptional tool for the study of dyskinesias induced by dopamine-like agents. Several such agents have been tested during the past 15 years, and it has been found that the duration of action of these compounds is the most reliable variable with which to predict their dyskinesiogenic profile. It is proposed that <ce:small-caps>l</ce:small-caps>-dopa-induced dyskinesias represent a form of pathological learning caused by chronic pulsatile (non physiological) stimulation of dopamine receptors, which activates a cascade of molecular and biochemical events. These events include defective regulation of Fos proteins that belong to the ΔFosB family, increased expression of neuropeptides, and defective GABA- and glutamate-mediated neurotransmission in the output structures of the basal ganglia.</ce:simple-para></ce:abstract-sec></ce:abstract></head><tail><ce:bibliography><ce:section-title>Selected references</ce:section-title><ce:bibliography-sec><ce:bib-reference id="bib1"><ce:label>1</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Olanow</ce:surname><ce:given-name>C.W.</ce:given-name></sb:author><sb:author><ce:surname>Koller</ce:surname><ce:given-name>W.C.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Neurology</sb:maintitle></sb:title><sb:volume-nr>50</sb:volume-nr></sb:series><sb:issue-nr>Suppl. 3</sb:issue-nr><sb:date>1998</sb:date></sb:issue><sb:pages><sb:first-page>S1</sb:first-page><sb:last-page>S57</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib2"><ce:label>2</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Mones</ce:surname><ce:given-name>R.J.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Analysis of <ce:small-caps>l</ce:small-caps>-dopa induced dyskinesias in 51 patients with Parkinsonism</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Neural. Neurosurg. Psychiatry</sb:maintitle></sb:title><sb:volume-nr>34</sb:volume-nr></sb:series><sb:date>1971</sb:date></sb:issue><sb:pages><sb:first-page>668</sb:first-page><sb:last-page>673</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib3"><ce:label>3</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Blanchet</ce:surname><ce:given-name>P.J.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Risk factors for peak dose dyskinesia in 100 <ce:small-caps>l</ce:small-caps>-dopa-treated parkinsonian patients</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Can. J. Neural. Sci.</sb:maintitle></sb:title><sb:volume-nr>23</sb:volume-nr></sb:series><sb:date>1996</sb:date></sb:issue><sb:pages><sb:first-page>189</sb:first-page><sb:last-page>193</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib4"><ce:label>4</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Fahn</ce:surname><ce:given-name>S.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>The spectrum of <ce:small-caps>l</ce:small-caps>-dopa-induced dyskinesias</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Ann. Neural.</sb:maintitle></sb:title><sb:volume-nr>47</sb:volume-nr></sb:series><sb:issue-nr>Suppl. 1</sb:issue-nr><sb:date>2000</sb:date></sb:issue><sb:pages><sb:first-page>S2</sb:first-page><sb:last-page>S11</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib5"><ce:label>5</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Grandas</ce:surname><ce:given-name>F.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Risk factors for <ce:small-caps>l</ce:small-caps>-dopa-induced dyskinesias in Parkinson's disease</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Neural.</sb:maintitle></sb:title><sb:volume-nr>246</sb:volume-nr></sb:series><sb:date>1999</sb:date></sb:issue><sb:pages><sb:first-page>1127</sb:first-page><sb:last-page>1133</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib6"><ce:label>6</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Nutt</ce:surname><ce:given-name>J.G.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle><ce:small-caps>l</ce:small-caps>-dopa-induced dyskinesia: review, observations, and speculations</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Neurology</sb:maintitle></sb:title><sb:volume-nr>40</sb:volume-nr></sb:series><sb:date>1990</sb:date></sb:issue><sb:pages><sb:first-page>340</sb:first-page><sb:last-page>345</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib7"><ce:label>7</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Nutt</ce:surname><ce:given-name>J.G.</ce:given-name></sb:author><sb:author><ce:surname>Holford</ce:surname><ce:given-name>N.H.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>The response to <ce:small-caps>l</ce:small-caps>-dopa in Parkinson's disease: imposing pharmacological law and order</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Ann. Neural.</sb:maintitle></sb:title><sb:volume-nr>39</sb:volume-nr></sb:series><sb:date>1996</sb:date></sb:issue><sb:pages><sb:first-page>561</sb:first-page><sb:last-page>573</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib8"><ce:label>8</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Langston</ce:surname><ce:given-name>J.W.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Investigating <ce:small-caps>l</ce:small-caps>-dopa-induced dyskinesias in the parkinsonian primate</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Ann. Neurol.</sb:maintitle></sb:title><sb:volume-nr>47</sb:volume-nr></sb:series><sb:issue-nr>Suppl. 1</sb:issue-nr><sb:date>2000</sb:date></sb:issue><sb:pages><sb:first-page>S79</sb:first-page><sb:last-page>S89</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib9"><ce:label>9</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Clarke</ce:surname><ce:given-name>C.E.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle><ce:small-caps>l</ce:small-caps>-dopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Neurol. Sci.</sb:maintitle></sb:title><sb:volume-nr>78</sb:volume-nr></sb:series><sb:date>1987</sb:date></sb:issue><sb:pages><sb:first-page>273</sb:first-page><sb:last-page>280</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib10"><ce:label>10</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Rajput</ce:surname><ce:given-name>A.H.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Is <ce:small-caps>l</ce:small-caps>-dopa toxic to human substantia nigra?</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Mov. Disord.</sb:maintitle></sb:title><sb:volume-nr>12</sb:volume-nr></sb:series><sb:date>1997</sb:date></sb:issue><sb:pages><sb:first-page>634</sb:first-page><sb:last-page>638</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib11"><ce:label>11</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Pearce</ce:surname><ce:given-name>R.K.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle><ce:small-caps>l</ce:small-caps>-dopa and dyskinesias in normal monkeys</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Mov. Disord.</sb:maintitle></sb:title><sb:volume-nr>14</sb:volume-nr></sb:series><sb:issue-nr>Suppl. 1</sb:issue-nr><sb:date>1999</sb:date></sb:issue><sb:pages><sb:first-page>9</sb:first-page><sb:last-page>12</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib12"><ce:label>12</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Zeng</ce:surname><ce:given-name>B.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Alterations in preproenkephalin and adenosine-2a receptor mRNA, but not preprotachykinin mRNA correlate with occurrence of dyskinesia in normal monkeys chronically treated with <ce:small-caps>l</ce:small-caps>-DOPA</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Eur. J. Neurosci.</sb:maintitle></sb:title><sb:volume-nr>12</sb:volume-nr></sb:series><sb:date>2000</sb:date></sb:issue><sb:pages><sb:first-page>1096</sb:first-page><sb:last-page>1104</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib13"><ce:label>13</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Limousin-Dowsey</ce:surname><ce:given-name>P.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Thalamic, subthalamic nucleus and internal pallidum stimulation in Parkinson's disease</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Neurol.</sb:maintitle></sb:title><sb:volume-nr>246</sb:volume-nr></sb:series><sb:issue-nr>Suppl. 2</sb:issue-nr><sb:date>1999</sb:date></sb:issue><sb:pages><sb:first-page>1142</sb:first-page><sb:last-page>1145</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib14"><ce:label>14</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Lang</ce:surname><ce:given-name>A.E.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Surgery for <ce:small-caps>l</ce:small-caps>-dopa-induced dyskinesias</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Ann. Neural.</sb:maintitle></sb:title><sb:volume-nr>47</sb:volume-nr></sb:series><sb:issue-nr>Suppl. 1</sb:issue-nr><sb:date>2000</sb:date></sb:issue><sb:pages><sb:first-page>S193</sb:first-page><sb:last-page>S202</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib15"><ce:label>15</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Baron</ce:surname><ce:given-name>M.S.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Treatment of advanced Parkinson's disease by posterior GPi pallidotomy: 1-year results of a pilot study</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Ann. Neurol.</sb:maintitle></sb:title><sb:volume-nr>40</sb:volume-nr></sb:series><sb:date>1996</sb:date></sb:issue><sb:pages><sb:first-page>355</sb:first-page><sb:last-page>366</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib16"><ce:label>16</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Krack</ce:surname><ce:given-name>P.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Inhibition of <ce:small-caps>l</ce:small-caps>-dopa effects by internal pallidal stimulation</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Mov. Disord.</sb:maintitle></sb:title><sb:volume-nr>13</sb:volume-nr></sb:series><sb:date>1998</sb:date></sb:issue><sb:pages><sb:first-page>648</sb:first-page><sb:last-page>652</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib17"><ce:label>17</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Benabid</ce:surname><ce:given-name>A.L.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Dyskinesias and the subthalamic nucleus</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Ann. Neural.</sb:maintitle></sb:title><sb:volume-nr>47</sb:volume-nr></sb:series><sb:issue-nr>Suppl. 1</sb:issue-nr><sb:date>2000</sb:date></sb:issue><sb:pages><sb:first-page>S189</sb:first-page><sb:last-page>S192</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib18"><ce:label>18</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Blanchet</ce:surname><ce:given-name>P.J.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Excitotoxic lateral pallidotomy does not relieve <ce:small-caps>l</ce:small-caps>-dopa-induced dyskinesia in MPTP parkinsonian monkeys</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Brain Res.</sb:maintitle></sb:title><sb:volume-nr>650</sb:volume-nr></sb:series><sb:date>1994</sb:date></sb:issue><sb:pages><sb:first-page>32</sb:first-page><sb:last-page>39</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib19"><ce:label>19</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Guridi</ce:surname><ce:given-name>J.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Subthalamotomy in parkinsonian monkeys. Behavioural and biochemical analysis</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Brain</sb:maintitle></sb:title><sb:volume-nr>119</sb:volume-nr></sb:series><sb:date>1996</sb:date></sb:issue><sb:pages><sb:first-page>1717</sb:first-page><sb:last-page>1727</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib20"><ce:label>20</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Metman</ce:surname><ce:given-name>L.V.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Pathophysiology of motor response complications in Parkinson's disease: hypotheses on the why, where, and what</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Mov. Disord.</sb:maintitle></sb:title><sb:volume-nr>15</sb:volume-nr></sb:series><sb:date>2000</sb:date></sb:issue><sb:pages><sb:first-page>3</sb:first-page><sb:last-page>8</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib21"><ce:label>21</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Schultz</ce:surname><ce:given-name>W.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Predictive reward signal of dopamine neurons</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Neurophysiol.</sb:maintitle></sb:title><sb:volume-nr>80</sb:volume-nr></sb:series><sb:date>1998</sb:date></sb:issue><sb:pages><sb:first-page>1</sb:first-page><sb:last-page>27</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib22"><ce:label>22</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Mengual</ce:surname><ce:given-name>E.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Thalamic interaction between the input and the output systems of the basal ganglia</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Chem. Neuroanat.</sb:maintitle></sb:title><sb:volume-nr>16</sb:volume-nr></sb:series><sb:date>1999</sb:date></sb:issue><sb:pages><sb:first-page>187</sb:first-page><sb:last-page>200</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib23"><ce:label>23</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Parent</ce:surname><ce:given-name>A.</ce:given-name></sb:author><sb:author><ce:surname>Hazrati</ce:surname><ce:given-name>L.N.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Functional anatomy of the basal ganglia. I. The cortico-basal ganglia- thalamo-cortical loop</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Brain Res. Rev.</sb:maintitle></sb:title><sb:volume-nr>20</sb:volume-nr></sb:series><sb:date>1995</sb:date></sb:issue><sb:pages><sb:first-page>91</sb:first-page><sb:last-page>127</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib24"><ce:label>24</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Verma</ce:surname><ce:given-name>A.</ce:given-name></sb:author><sb:author><ce:surname>Moghaddam</ce:surname><ce:given-name>B.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Regulation of striatal dopamine release by metabotropic glutamate receptors</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Synapse</sb:maintitle></sb:title><sb:volume-nr>28</sb:volume-nr></sb:series><sb:date>1998</sb:date></sb:issue><sb:pages><sb:first-page>220</sb:first-page><sb:last-page>226</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib25"><ce:label>25</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Wu</ce:surname><ce:given-name>Y.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Inhibitory glutamatergic regulation of evoked dopamine release in striatum</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Neuroscience</sb:maintitle></sb:title><sb:volume-nr>96</sb:volume-nr></sb:series><sb:date>2000</sb:date></sb:issue><sb:pages><sb:first-page>65</sb:first-page><sb:last-page>72</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib26"><ce:label>26</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Chase</ce:surname><ce:given-name>T.N.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Drugs</sb:maintitle></sb:title><sb:volume-nr>55</sb:volume-nr></sb:series><sb:issue-nr>Suppl. 1</sb:issue-nr><sb:date>1998</sb:date></sb:issue><sb:pages><sb:first-page>1</sb:first-page><sb:last-page>9</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib27"><ce:label>27</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Bedard</ce:surname><ce:given-name>P.J.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Chronic treatment with <ce:small-caps>l</ce:small-caps>-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys</sb:maintitle></sb:title></sb:contribution><sb:host><sb:edited-book><sb:title><sb:maintitle>Correlation with [<ce:sup loc="post">3</ce:sup>H]spiperone binding</sb:maintitle></sb:title><sb:book-series><sb:series><sb:title><sb:maintitle>Brain Res.</sb:maintitle></sb:title><sb:volume-nr>379</sb:volume-nr></sb:series></sb:book-series><sb:date>1986</sb:date></sb:edited-book><sb:pages><sb:first-page>294</sb:first-page><sb:last-page>299</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib28"><ce:label>28</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Calon</ce:surname><ce:given-name>F.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle><ce:small-caps>l</ce:small-caps>-dopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABA<ce:inf loc="post">A</ce:inf> receptors in the striatopallidal complex</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Brain Res</sb:maintitle></sb:title><sb:volume-nr>680</sb:volume-nr></sb:series><sb:date>1995</sb:date></sb:issue><sb:pages><sb:first-page>43</sb:first-page><sb:last-page>52</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib29"><ce:label>29</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Falardeau</ce:surname><ce:given-name>P.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Behavioral and biochemical effect of chronic treatment with D-1 and/or D-2 dopamine agonists in MPTP monkeys</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Eur. J. Pharmacol.</sb:maintitle></sb:title><sb:volume-nr>150</sb:volume-nr></sb:series><sb:date>1988</sb:date></sb:issue><sb:pages><sb:first-page>59</sb:first-page><sb:last-page>66</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib30"><ce:label>30</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Rascal</ce:surname><ce:given-name>A.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Long-term treatment of Parkinson's disease with bromocriptine</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Neural. Neurosurg. Psychiatry</sb:maintitle></sb:title><sb:volume-nr>42</sb:volume-nr></sb:series><sb:date>1979</sb:date></sb:issue><sb:pages><sb:first-page>143</sb:first-page><sb:last-page>150</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib31"><ce:label>31</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Blanchet</ce:surname><ce:given-name>P.J.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U- 91356A) in MPTP-exposed monkeys</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Pharmacol. Exp. Ther.</sb:maintitle></sb:title><sb:volume-nr>272</sb:volume-nr></sb:series><sb:date>1995</sb:date></sb:issue><sb:pages><sb:first-page>854</sb:first-page><sb:last-page>859</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib32"><ce:label>32</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Gomez-Mancilla</ce:surname><ce:given-name>B.</ce:given-name></sb:author><sb:author><ce:surname>Bedard</ce:surname><ce:given-name>P.J.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Effect of chronic treatment with (+)-PHNO, a D2 agonist in MPTP-treated monkeys</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Exp. Neurol.</sb:maintitle></sb:title><sb:volume-nr>117</sb:volume-nr></sb:series><sb:date>1992</sb:date></sb:issue><sb:pages><sb:first-page>185</sb:first-page><sb:last-page>188</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib33"><ce:label>33</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Blanchet</ce:surname><ce:given-name>P.J.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Dyskinesia and wearing-off following dopamine D1 agonist treatment in drug-naive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned primates</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Mov. Disord.</sb:maintitle></sb:title><sb:volume-nr>11</sb:volume-nr></sb:series><sb:date>1996</sb:date></sb:issue><sb:pages><sb:first-page>91</sb:first-page><sb:last-page>94</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib34"><ce:label>34</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Jenner</ce:surname><ce:given-name>P.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Ann. Neurol.</sb:maintitle></sb:title><sb:volume-nr>47</sb:volume-nr></sb:series><sb:issue-nr>Suppl. 1</sb:issue-nr><sb:date>2000</sb:date></sb:issue><sb:pages><sb:first-page>S90</sb:first-page><sb:last-page>S104</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib35"><ce:label>35</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Pearce</ce:surname><ce:given-name>R.K.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>De novo administration of ropinirole and bromocriptine induces less dyskinesia than <ce:small-caps>l</ce:small-caps>-dopa in the MPTPtreated marmoset</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Mov. Disord.</sb:maintitle></sb:title><sb:volume-nr>13</sb:volume-nr></sb:series><sb:date>1998</sb:date></sb:issue><sb:pages><sb:first-page>234</sb:first-page><sb:last-page>241</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib36"><ce:label>36</ce:label><sb:reference><sb:comment>056 Study Group</sb:comment><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Rascol</ce:surname><ce:given-name>O.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or <ce:small-caps>l</ce:small-caps>-dopa</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>New Engl. J. Med.</sb:maintitle></sb:title><sb:volume-nr>342</sb:volume-nr></sb:series><sb:date>2000</sb:date></sb:issue><sb:pages><sb:first-page>1484</sb:first-page><sb:last-page>1491</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib37"><ce:label>37</ce:label><sb:reference><sb:comment>The PKDS009 Study Group</sb:comment><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Rinne</ce:surname><ce:given-name>U.K.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:title><sb:maintitle>Results of a double-blind <ce:small-caps>l</ce:small-caps>-dopa controlled trial</sb:maintitle></sb:title><sb:series><sb:title><sb:maintitle>Drugs</sb:maintitle></sb:title><sb:volume-nr>55</sb:volume-nr></sb:series><sb:issue-nr>Suppl. 1</sb:issue-nr><sb:date>1998</sb:date></sb:issue><sb:pages><sb:first-page>23</sb:first-page><sb:last-page>30</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib38"><ce:label>38</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Goulet</ce:surname><ce:given-name>M.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Dyskinesias and tolerance induced by chronic treatment with a D1 agonist administered in pulsatile or continuous mode do not correlate with changes of putaminal D1 receptors in drug-naïve MPTP monkeys</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Brain Res.</sb:maintitle></sb:title><sb:volume-nr>719</sb:volume-nr></sb:series><sb:date>1996</sb:date></sb:issue><sb:pages><sb:first-page>129</sb:first-page><sb:last-page>137</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib39"><ce:label>39</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Blanchet</ce:surname><ce:given-name>P.J.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Dopamine D1 receptor desensitization profile in MPTP-lesioned primates</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Eur. J. Pharmacol.</sb:maintitle></sb:title><sb:volume-nr>309</sb:volume-nr></sb:series><sb:date>1996</sb:date></sb:issue><sb:pages><sb:first-page>13</sb:first-page><sb:last-page>20</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib40"><ce:label>40</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Grondin</ce:surname><ce:given-name>R.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Dl receptor blockade improves <ce:small-caps>l</ce:small-caps>-dopainduced dyskinesia but worsens parkinsonism in MPTP monkeys</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Neurology</sb:maintitle></sb:title><sb:volume-nr>52</sb:volume-nr></sb:series><sb:date>1999</sb:date></sb:issue><sb:pages><sb:first-page>771</sb:first-page><sb:last-page>776</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib41"><ce:label>41</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Morissette</ce:surname><ce:given-name>M.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Changes of D1 and D2 dopamine receptor mRNA in the brains of monkeys lesioned with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: correction with chronic administration of L-3,4-dihydroxyphenylalanine</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Mol. Pharmacol.</sb:maintitle></sb:title><sb:volume-nr>50</sb:volume-nr></sb:series><sb:date>1996</sb:date></sb:issue><sb:pages><sb:first-page>1073</sb:first-page><sb:last-page>1079</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib42"><ce:label>42</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Grondin</ce:surname><ce:given-name>R.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Dopamine D1 receptor mRNA and receptor levels in the striatum of MPTP monkeys chronically treated with SKF-82958</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Eur. J. Pharmacol.</sb:maintitle></sb:title><sb:volume-nr>378</sb:volume-nr></sb:series><sb:date>1999</sb:date></sb:issue><sb:pages><sb:first-page>259</sb:first-page><sb:last-page>263</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib43"><ce:label>43</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Muriel</ce:surname><ce:given-name>M.P.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle><ce:small-caps>l</ce:small-caps>-dopa induces a cytoplasmic localization of D1 dopamine receptors in striatal neurons in Parkinson's disease</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Ann. Neurol.</sb:maintitle></sb:title><sb:volume-nr>46</sb:volume-nr></sb:series><sb:date>1999</sb:date></sb:issue><sb:pages><sb:first-page>103</sb:first-page><sb:last-page>111</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib44"><ce:label>44</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Dumartin</ce:surname><ce:given-name>B.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Internalization of D1 dopamine receptor in striatal neurons <ce:italic>in vivo</ce:italic> as evidence of activation by dopamine agonists</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Neurosci.</sb:maintitle></sb:title><sb:volume-nr>18</sb:volume-nr></sb:series><sb:date>1998</sb:date></sb:issue><sb:pages><sb:first-page>1650</sb:first-page><sb:last-page>1661</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib45"><ce:label>45</ce:label><ce:other-ref><ce:textref>Goulet, M. <ce:italic>et al.</ce:italic> Regulation by chronic treatment with cabergoline of dopamine D1 and D2 receptor levels and their expression in the striatum of parkinsonian monkeys. <ce:italic>Prog. Neuropsychopharmacol. Biol. Psychiatry</ce:italic> (in press)</ce:textref></ce:other-ref></ce:bib-reference><ce:bib-reference id="bib46"><ce:label>46</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Goulet</ce:surname><ce:given-name>M.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drug-naive 4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain Dl and D2 receptor expression: <ce:italic>in situ</ce:italic> hybridization histochemical analysis</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Neuroscience</sb:maintitle></sb:title><sb:volume-nr>79</sb:volume-nr></sb:series><sb:date>1997</sb:date></sb:issue><sb:pages><sb:first-page>497</sb:first-page><sb:last-page>507</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib47"><ce:label>47</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Graveland</ce:surname><ce:given-name>G.A.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>A Golgi study of the human neostriatum: neurons and afferent fibers</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Comp. Neurol.</sb:maintitle></sb:title><sb:volume-nr>234</sb:volume-nr></sb:series><sb:date>1985</sb:date></sb:issue><sb:pages><sb:first-page>317</sb:first-page><sb:last-page>333</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib48"><ce:label>48</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Kita</ce:surname><ce:given-name>H.</ce:given-name></sb:author><sb:author><ce:surname>Kitai</ce:surname><ce:given-name>S.T.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Glutamate decarboxylase immunoreactive neurons in rat neostriatum: their morphological types and populations</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Brain Res.</sb:maintitle></sb:title><sb:volume-nr>447</sb:volume-nr></sb:series><sb:date>1988</sb:date></sb:issue><sb:pages><sb:first-page>346</sb:first-page><sb:last-page>352</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib49"><ce:label>49</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Smith</ce:surname><ce:given-name>A.D.</ce:given-name></sb:author><sb:author><ce:surname>Bolam</ce:surname><ce:given-name>J.P.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>The neural network of the basal ganglia as revealed by the study of synaptic connections of identified neurones</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Trends Neurosci.</sb:maintitle></sb:title><sb:volume-nr>13</sb:volume-nr></sb:series><sb:date>1990</sb:date></sb:issue><sb:pages><sb:first-page>259</sb:first-page><sb:last-page>265</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib50"><ce:label>50</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Calabresi</ce:surname><ce:given-name>P.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle><ce:small-caps>l</ce:small-caps>-dopa-induced dyskinesia: a pathological form of striatal synaptic plasticity?</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Ann. Neurol.</sb:maintitle></sb:title><sb:volume-nr>47</sb:volume-nr></sb:series><sb:issue-nr>Suppl. 1</sb:issue-nr><sb:date>2000</sb:date></sb:issue><sb:pages><sb:first-page>S60</sb:first-page><sb:last-page>S69</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib51"><ce:label>51</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Cepeda</ce:surname><ce:given-name>C.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Neuromodulatory actions of dopamine in the neostriatum are dependent upon the excitatory amino acid receptor subtypes activated</sb:maintitle></sb:title></sb:contribution><sb:host><sb:edited-book><sb:book-series><sb:series><sb:title><sb:maintitle>Proc. Natl. Acad. Sci. U. S. A.</sb:maintitle></sb:title><sb:volume-nr>90</sb:volume-nr></sb:series></sb:book-series><sb:date>1993</sb:date></sb:edited-book><sb:pages><sb:first-page>9576</sb:first-page><sb:last-page>9580</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib52"><ce:label>52</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Kotter</ce:surname><ce:given-name>R.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Postsynaptic integration of glutamatergic and dopaminergic signals in the striatum</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Prog. Neurobiol.</sb:maintitle></sb:title><sb:volume-nr>44</sb:volume-nr></sb:series><sb:date>1994</sb:date></sb:issue><sb:pages><sb:first-page>163</sb:first-page><sb:last-page>196</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib53"><ce:label>53</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Oh</ce:surname><ce:given-name>J.D.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Protein kinase A inhibitor attenuates <ce:small-caps>l</ce:small-caps>-dopainduced motor response alterations in the hemi-parkinsonian rat</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Neurosci. Lett.</sb:maintitle></sb:title><sb:volume-nr>228</sb:volume-nr></sb:series><sb:date>1997</sb:date></sb:issue><sb:pages><sb:first-page>5</sb:first-page><sb:last-page>8</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib54"><ce:label>54</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Oh</ce:surname><ce:given-name>J.D.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Enhanced tyrosine phosphorylation of striatal NMDA receptor subunits: effect of dopaminergic denervation and <ce:small-caps>l</ce:small-caps>-DOPA administration</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Brain Res.</sb:maintitle></sb:title><sb:volume-nr>813</sb:volume-nr></sb:series><sb:date>1998</sb:date></sb:issue><sb:pages><sb:first-page>150</sb:first-page><sb:last-page>159</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib55"><ce:label>55</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Oh</ce:surname><ce:given-name>J.D.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Effect of dopamine denervation and dopamine agonist administration on serine phosphorylation of striatal NMDA receptor subunits</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Brain Res.</sb:maintitle></sb:title><sb:volume-nr>821</sb:volume-nr></sb:series><sb:date>1999</sb:date></sb:issue><sb:pages><sb:first-page>433</sb:first-page><sb:last-page>442</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib56"><ce:label>56</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Dunah</ce:surname><ce:given-name>A.W.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Alterations in subunit expression, composition, and phosphorylation of striatal <ce:italic>N</ce:italic>-methyl-<ce:small-caps>d</ce:small-caps>-aspartate glutamate receptors in a rat 6-hydroxydopamine model of Parkinson's disease</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Mol. Pharmacol.</sb:maintitle></sb:title><sb:volume-nr>57</sb:volume-nr></sb:series><sb:date>2000</sb:date></sb:issue><sb:pages><sb:first-page>342</sb:first-page><sb:last-page>352</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib57"><ce:label>57</ce:label><sb:reference><sb:comment>(Suppl. <ce:italic>Basal ganglia, Parkinson's disease and levodopa therapy</ce:italic>)</sb:comment><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Chase</ce:surname><ce:given-name>T.N.</ce:given-name></sb:author><sb:author><ce:surname>Oh</ce:surname><ce:given-name>J.D.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Striatal dopamine- and glutamate-mediated dysregulation in experimental parkinsonism</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Trends Neurosci.</sb:maintitle></sb:title><sb:volume-nr>23</sb:volume-nr></sb:series><sb:date>2000</sb:date></sb:issue><sb:pages><sb:first-page>S86</sb:first-page><sb:last-page>S91</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib58"><ce:label>58</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Bezard</ce:surname><ce:given-name>E.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Riluzole delayed appearance of parkinsonian motor abnormalities in a chronic MPTP monkey model</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Eur. J. Pharmacol.</sb:maintitle></sb:title><sb:volume-nr>356</sb:volume-nr></sb:series><sb:date>1998</sb:date></sb:issue><sb:pages><sb:first-page>101</sb:first-page><sb:last-page>104</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib59"><ce:label>59</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Blanchet</ce:surname><ce:given-name>P.J.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Differing effects of <ce:italic>N</ce:italic>-methyl-<ce:small-caps>d</ce:small-caps>-aspartate receptor subtype selective antagonists on dyskinesias in <ce:small-caps>l</ce:small-caps>-dopatreated 1-methyl-4-phenyl- tetrahydropyridine monkeys</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Pharmacol. Exp. Ther.</sb:maintitle></sb:title><sb:volume-nr>290</sb:volume-nr></sb:series><sb:date>1999</sb:date></sb:issue><sb:pages><sb:first-page>1034</sb:first-page><sb:last-page>1040</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib60"><ce:label>60</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Blanchet</ce:surname><ce:given-name>P.J.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Modulation of <ce:small-caps>l</ce:small-caps>-dopa-induced motor response complications by NMDA antagonists in Parkinson's disease</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Neurosci. Biobehav. Rev.</sb:maintitle></sb:title><sb:volume-nr>21</sb:volume-nr></sb:series><sb:date>1997</sb:date></sb:issue><sb:pages><sb:first-page>447</sb:first-page><sb:last-page>453</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib61"><ce:label>61</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Verhagen Metman</ce:surname><ce:given-name>L.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Blockade of glutamatergic transmission as treatment for dyskinesias and motor fluctuations in Parkinson's disease</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Amino Acids</sb:maintitle></sb:title><sb:volume-nr>14</sb:volume-nr></sb:series><sb:date>1998</sb:date></sb:issue><sb:pages><sb:first-page>75</sb:first-page><sb:last-page>82</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib62"><ce:label>62</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Papa</ce:surname><ce:given-name>S.M.</ce:given-name></sb:author><sb:author><ce:surname>Chase</ce:surname><ce:given-name>T.N.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle><ce:small-caps>l</ce:small-caps>-dopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Ann. Neurol.</sb:maintitle></sb:title><sb:volume-nr>39</sb:volume-nr></sb:series><sb:date>1996</sb:date></sb:issue><sb:pages><sb:first-page>574</sb:first-page><sb:last-page>578</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib63"><ce:label>63</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Morissette</ce:surname><ce:given-name>M.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: comparison with <ce:small-caps>l</ce:small-caps>-DOPA therapy</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Mol. Brain Res.</sb:maintitle></sb:title><sb:volume-nr>49</sb:volume-nr></sb:series><sb:date>1997</sb:date></sb:issue><sb:pages><sb:first-page>55</sb:first-page><sb:last-page>62</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib64"><ce:label>64</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Morissette</ce:surname><ce:given-name>M.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Differential regulation of striatal preproenkephalin and preprotachykinin mRNA levels in MPTP-lesioned monkeys chronically treated with dopamine D1 or D2 receptor agonists</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Neurochem.</sb:maintitle></sb:title><sb:volume-nr>72</sb:volume-nr></sb:series><sb:date>1999</sb:date></sb:issue><sb:pages><sb:first-page>682</sb:first-page><sb:last-page>692</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib65"><ce:label>65</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Herrero</ce:surname><ce:given-name>M.T.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Effects of <ce:small-caps>l</ce:small-caps>-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Neuroscience</sb:maintitle></sb:title><sb:volume-nr>68</sb:volume-nr></sb:series><sb:date>1995</sb:date></sb:issue><sb:pages><sb:first-page>1189</sb:first-page><sb:last-page>1198</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib66"><ce:label>66</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Gerfen</ce:surname><ce:given-name>C.R.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Dopamine-mediated gene regulation in models of Parkinson's disease</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Ann. Neurol.</sb:maintitle></sb:title><sb:volume-nr>47</sb:volume-nr></sb:series><sb:issue-nr>Suppl. 1</sb:issue-nr><sb:date>2000</sb:date></sb:issue><sb:pages><sb:first-page>S42</sb:first-page><sb:last-page>S50</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib67"><ce:label>67</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Hyman</ce:surname><ce:given-name>S.E.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Dopamine regulation of transcription factor-target interactions in rat striatum</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Chem. Senses</sb:maintitle></sb:title><sb:volume-nr>20</sb:volume-nr></sb:series><sb:date>1995</sb:date></sb:issue><sb:pages><sb:first-page>257</sb:first-page><sb:last-page>260</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib68"><ce:label>68</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Nestler</ce:surname><ce:given-name>E.J.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>AFosB: a molecular mediator of long-term neural and behavioral plasticity</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Brain Res.</sb:maintitle></sb:title><sb:volume-nr>835</sb:volume-nr></sb:series><sb:date>1999</sb:date></sb:issue><sb:pages><sb:first-page>10</sb:first-page><sb:last-page>17</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib69"><ce:label>69</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Doucet</ce:surname><ce:given-name>J.P.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Chrohie-alterations in dopaminergic neurotransmission produce a persistent elevation of ΔFosB-like protein(s) in both the rodent and primate striatum</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Eur. J. Neurosci.</sb:maintitle></sb:title><sb:volume-nr>8</sb:volume-nr></sb:series><sb:date>1996</sb:date></sb:issue><sb:pages><sb:first-page>365</sb:first-page><sb:last-page>381</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib70"><ce:label>70</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Hiroi</ce:surname><ce:given-name>N.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Essential role of the fosB gene in molecular, cellular, and behavioral actions of chronic electroconvulsive seizures</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Neurosci.</sb:maintitle></sb:title><sb:volume-nr>18</sb:volume-nr></sb:series><sb:date>1998</sb:date></sb:issue><sb:pages><sb:first-page>6952</sb:first-page><sb:last-page>6962</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib71"><ce:label>71</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Calon</ce:surname><ce:given-name>F.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Molecular basis of <ce:small-caps>l</ce:small-caps>-dopa-induced dyskinesias</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Ann. Neurol.</sb:maintitle></sb:title><sb:volume-nr>47</sb:volume-nr></sb:series><sb:issue-nr>Suppl. 1</sb:issue-nr><sb:date>2000</sb:date></sb:issue><sb:pages><sb:first-page>S70</sb:first-page><sb:last-page>S78</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib72"><ce:label>72</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Tamminga</ce:surname><ce:given-name>C.A.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Improvement in tardive dyskinesia after muscimol therapy</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Arch. Gen. Psychiatry</sb:maintitle></sb:title><sb:volume-nr>36</sb:volume-nr></sb:series><sb:date>1979</sb:date></sb:issue><sb:pages><sb:first-page>595</sb:first-page><sb:last-page>598</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib73"><ce:label>73</ce:label><sb:reference><sb:comment>(Suppl.)</sb:comment><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Tamminga</ce:surname><ce:given-name>C.A.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>GABA dysfunction in the pathophysiology of tardive dyskinesia</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Psychopharmacology</sb:maintitle></sb:title><sb:volume-nr>2</sb:volume-nr></sb:series><sb:date>1985</sb:date></sb:issue><sb:pages><sb:first-page>122</sb:first-page><sb:last-page>127</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib74"><ce:label>74</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Thaker</ce:surname><ce:given-name>G.K.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Brain gamma-aminobutyric acid abnormality in tardive dyskinesia</sb:maintitle></sb:title></sb:contribution><sb:host><sb:edited-book><sb:title><sb:maintitle>Reduction in cerebrospinal fluid GABA levels and therapeutic response to GABA agonist treatment</sb:maintitle></sb:title><sb:book-series><sb:series><sb:title><sb:maintitle>Arch. Gen. Psychiatry</sb:maintitle></sb:title><sb:volume-nr>44</sb:volume-nr></sb:series></sb:book-series><sb:date>1987</sb:date></sb:edited-book><sb:pages><sb:first-page>522</sb:first-page><sb:last-page>529</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib75"><ce:label>75</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Calon</ce:surname><ce:given-name>F.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Chronic D1 and D2 dopaminomimetic treatment of MPTP-denervated monkeys: effects on basal ganglia GABA(A)/benzodiazepine receptor complex and GABA content</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Neurochem. Int.</sb:maintitle></sb:title><sb:volume-nr>35</sb:volume-nr></sb:series><sb:date>1999</sb:date></sb:issue><sb:pages><sb:first-page>81</sb:first-page><sb:last-page>91</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib76"><ce:label>76</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Gnanalingham</ce:surname><ce:given-name>K.K.</ce:given-name></sb:author><sb:author><ce:surname>Robertson</ce:surname><ce:given-name>R.G.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Chronic continuous and intermittent L-3,4-dihydroxyphenylalanine treatments differentially affect basal ganglia function in 6-hydroxydopamine lesioned rats — an autoradiographic study using [3H]flunitrazepam</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Neuroscience</sb:maintitle></sb:title><sb:volume-nr>57</sb:volume-nr></sb:series><sb:date>1993</sb:date></sb:issue><sb:pages><sb:first-page>673</sb:first-page><sb:last-page>681</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib77"><ce:label>77</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Pan</ce:surname><ce:given-name>H.S.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Gamma-aminobutyric acid and benzodiazepine receptor changes induced by unilateral 6-hydroxydopamine lesions of the medial forebrain bundle</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>J. Neurochem.</sb:maintitle></sb:title><sb:volume-nr>45</sb:volume-nr></sb:series><sb:date>1985</sb:date></sb:issue><sb:pages><sb:first-page>1396</sb:first-page><sb:last-page>1404</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib78"><ce:label>78</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Robertson</ce:surname><ce:given-name>R.G.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>The role of striatopallidal neurones utilizing gamma-aminobutyric acid in the pathophysiology of MPTP-induced parkinsonism in the primate: evidence from [3H]flunitrazepam autoradiography</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Brain Res.</sb:maintitle></sb:title><sb:volume-nr>531</sb:volume-nr></sb:series><sb:date>1990</sb:date></sb:issue><sb:pages><sb:first-page>95</sb:first-page><sb:last-page>104</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib79"><ce:label>79</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Calon</ce:surname><ce:given-name>F.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>1251-CGP 64213 binding to GABA(B) receptors in the brain of monkeys: effect of MPTP and dopaminomimetic treatments</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Exp. Neural.</sb:maintitle></sb:title><sb:volume-nr>163</sb:volume-nr></sb:series><sb:date>2000</sb:date></sb:issue><sb:pages><sb:first-page>191</sb:first-page><sb:last-page>199</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib80"><ce:label>80</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Delong</ce:surname><ce:given-name>M.R.</ce:given-name></sb:author></sb:authors><sb:title><sb:maintitle>Primate models of movement disorders of basal ganglia origin</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Trends Neurosci.</sb:maintitle></sb:title><sb:volume-nr>13</sb:volume-nr></sb:series><sb:date>1990</sb:date></sb:issue><sb:pages><sb:first-page>281</sb:first-page><sb:last-page>285</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib81"><ce:label>81</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Filion</ce:surname><ce:given-name>M.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Effects of dopamine agonists on the spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Brain Res.</sb:maintitle></sb:title><sb:volume-nr>547</sb:volume-nr></sb:series><sb:date>1991</sb:date></sb:issue><sb:pages><sb:first-page>152</sb:first-page><sb:last-page>161</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib82"><ce:label>82</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Albin</ce:surname><ce:given-name>R.L.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>The functional anatomy of basal ganglia disorders</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Trends Neurosci.</sb:maintitle></sb:title><sb:volume-nr>12</sb:volume-nr></sb:series><sb:date>1989</sb:date></sb:issue><sb:pages><sb:first-page>366</sb:first-page><sb:last-page>375</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib83"><ce:label>83</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Bedard</ce:surname><ce:given-name>P.J.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Dopamine-receptor families and the treatment of Parkinson's disease</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Clin. Neuropharmacol.</sb:maintitle></sb:title><sb:volume-nr>18</sb:volume-nr></sb:series><sb:date>1995</sb:date></sb:issue><sb:pages><sb:first-page>S178</sb:first-page><sb:last-page>S187</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib84"><ce:label>84</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Obeso</ce:surname><ce:given-name>J.A.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Pathophysiology of <ce:small-caps>l</ce:small-caps>-dopa-induced dyskinesias in Parkinson's disease: problems with the current model</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Ann. Neurol.</sb:maintitle></sb:title><sb:volume-nr>47</sb:volume-nr></sb:series><sb:issue-nr>Suppl. 1</sb:issue-nr><sb:date>2000</sb:date></sb:issue><sb:pages><sb:first-page>S22</sb:first-page><sb:last-page>S24</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib85"><ce:label>85</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Papa</ce:surname><ce:given-name>S.M.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Internal globus pallidus discharge is nearly suppressed during levod <ce:small-caps>l</ce:small-caps>-dopa-induced dyskinesias</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Ann. Neurol.</sb:maintitle></sb:title><sb:volume-nr>46</sb:volume-nr></sb:series><sb:date>1999</sb:date></sb:issue><sb:pages><sb:first-page>732</sb:first-page><sb:last-page>738</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference><ce:bib-reference id="bib86"><ce:label>86</ce:label><sb:reference><sb:contribution langtype="en"><sb:authors><sb:author><ce:surname>Boraud</ce:surname><ce:given-name>T.</ce:given-name></sb:author><sb:et-al></sb:et-al></sb:authors><sb:title><sb:maintitle>Effects of riluzole on the electrophysiological activity of pallidal neurons in the l-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkey</sb:maintitle></sb:title></sb:contribution><sb:host><sb:issue><sb:series><sb:title><sb:maintitle>Neurosci. Lett.</sb:maintitle></sb:title><sb:volume-nr>281</sb:volume-nr></sb:series><sb:date>2000</sb:date></sb:issue><sb:pages><sb:first-page>75</sb:first-page><sb:last-page>78</sb:last-page></sb:pages></sb:host></sb:reference></ce:bib-reference></ce:bibliography-sec></ce:bibliography></tail></article></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Dopamine-receptor stimulation: biobehavioral and biochemical consequences</title></titleInfo><titleInfo type="alternative" lang="en" contentType="CDATA"><title>Dopamine-receptor stimulation: biobehavioral and biochemical consequences</title></titleInfo><name type="personal"><namePart type="given">Frédéric</namePart><namePart type="family">Calon</namePart><affiliation>Oncology and Molecular Endocrinology Research Unit, Laval University Medical Center (CHUL), Québec, Canada GIV 4G2</affiliation><affiliation>Faculty of Pharmacy, Laval University, Québec, Canada GIK 7P4</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Abdallah Hadj</namePart><namePart type="family">Tahar</namePart><affiliation>Neuroscience Research Unit, Laval University Medical Center (CHUL), Québec, Canada G1V 4G2</affiliation><affiliation>Dept of Medicine, Faculty of Medicine, Laval University, Québec, Canada GIK 7P4</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Pierre J.</namePart><namePart type="family">Blanchet</namePart><affiliation>Neuroscience Research Unit, Laval University Medical Center (CHUL), Québec, Canada G1V 4G2</affiliation><affiliation>Dept of Medicine, Faculty of Medicine, Laval University, Québec, Canada GIK 7P4</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Marc</namePart><namePart type="family">Morissette</namePart><affiliation>Oncology and Molecular Endocrinology Research Unit, Laval University Medical Center (CHUL), Québec, Canada GIV 4G2</affiliation><affiliation>Faculty of Pharmacy, Laval University, Québec, Canada GIK 7P4</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Richard</namePart><namePart type="family">Grondin</namePart><affiliation>Oncology and Molecular Endocrinology Research Unit, Laval University Medical Center (CHUL), Québec, Canada GIV 4G2</affiliation><affiliation>Faculty of Pharmacy, Laval University, Québec, Canada GIK 7P4</affiliation><affiliation>Neuroscience Research Unit, Laval University Medical Center (CHUL), Québec, Canada G1V 4G2</affiliation><affiliation>Dept of Medicine, Faculty of Medicine, Laval University, Québec, Canada GIK 7P4</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Martin</namePart><namePart type="family">Goulet</namePart><affiliation>Oncology and Molecular Endocrinology Research Unit, Laval University Medical Center (CHUL), Québec, Canada GIV 4G2</affiliation><affiliation>Faculty of Pharmacy, Laval University, Québec, Canada GIK 7P4</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jean-Pierre</namePart><namePart type="family">Doucet</namePart><affiliation>Dept of Pharmacology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">George S.</namePart><namePart type="family">Robertson</namePart><affiliation>Dept of Pharmacology, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Eric</namePart><namePart type="family">Nestler</namePart><affiliation>Laboratory of Molecular Psychiatry and Yale Center for Genes and Behavior, Yale University School of Medicine and Connecticut Mental Health Center, New Haven, CT 06508, USA</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Thérèse</namePart><namePart type="family">Di Paolo</namePart><affiliation>Oncology and Molecular Endocrinology Research Unit, Laval University Medical Center (CHUL), Québec, Canada GIV 4G2</affiliation><affiliation>Faculty of Pharmacy, Laval University, Québec, Canada GIK 7P4</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Paul J.</namePart><namePart type="family">Bédard</namePart><affiliation>Neuroscience Research Unit, Laval University Medical Center (CHUL), Québec, Canada G1V 4G2</affiliation><affiliation>Dept of Medicine, Faculty of Medicine, Laval University, Québec, Canada GIK 7P4</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="review-article" displayLabel="Review article"></genre><originInfo><publisher>ELSEVIER</publisher><dateIssued encoding="w3cdtf">2000</dateIssued><copyrightDate encoding="w3cdtf">2000</copyrightDate></originInfo><language><languageTerm type="code" authority="iso639-2b">eng</languageTerm><languageTerm type="code" authority="rfc3066">en</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType></physicalDescription><abstract lang="en">The MPTP monkey is a well-characterized animal model of parkinsonism and provides an exceptional tool for the study of dyskinesias induced by dopamine-like agents. Several such agents have been tested during the past 15 years, and it has been found that the duration of action of these compounds is the most reliable variable with which to predict their dyskinesiogenic profile. It is proposed that l-dopa-induced dyskinesias represent a form of pathological learning caused by chronic pulsatile (non physiological) stimulation of dopamine receptors, which activates a cascade of molecular and biochemical events. These events include defective regulation of Fos proteins that belong to the ΔFosB family, increased expression of neuropeptides, and defective GABA- and glutamate-mediated neurotransmission in the output structures of the basal ganglia.</abstract><note type="content">Section title: Review</note><relatedItem type="host"><titleInfo><title>Trends in Neurosciences</title></titleInfo><titleInfo type="abbreviated"><title>TINS</title></titleInfo><genre type="journal">journal</genre><originInfo><dateIssued encoding="w3cdtf">200010</dateIssued></originInfo><identifier type="ISSN">0166-2236</identifier><identifier type="PII">S0166-2236(00)X0239-1</identifier><part><date>200010</date><detail type="volume"><number>23</number><caption>vol.</caption></detail><detail type="supplement"><number>S1</number><caption>Suppl.</caption></detail><extent unit="issue pages"><start>S1</start><end>S126</end></extent><extent unit="pages"><start>S92</start><end>S100</end></extent></part></relatedItem><identifier type="istex">F5021E916FA1644FC98FFA3C109970BDE219090A</identifier><identifier type="DOI">10.1016/S1471-1931(00)00026-4</identifier><identifier type="PII">S1471-1931(00)00026-4</identifier><identifier type="ArticleID">00000264</identifier><accessCondition type="use and reproduction" contentType="copyright">©2000 Elsevier Science Ltd. All rights reserved.</accessCondition><recordInfo><recordContentSource>ELSEVIER</recordContentSource><recordOrigin>Elsevier Science Ltd. All rights reserved., ©2000</recordOrigin></recordInfo></mods></metadata></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002681 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 002681 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:F5021E916FA1644FC98FFA3C109970BDE219090A
|texte= Dopamine-receptor stimulation: biobehavioral and biochemical consequences
}}
| This area was generated with Dilib version V0.6.29. |  |